Novel molecular targets for antimalarial chemotherapy.
The emergence and spread of drug-resistant malaria parasites is a serious public health problem in the tropical world. Malaria control has relied upon the traditional quinoline, antifolate and artemisinin compounds. Very few new antimalarials were developed in the last quarter of the 20th century. An alarming increase in drug-resistant strains of the malaria parasite poses a significant problem for effective control. Recent advances in our knowledge of parasite biology as well as the availability of the genome sequence provide a wide range of novel targets for drug design. Gene products involved in controlling vital aspects of parasite metabolism and organelle function could be attractive targets. It is expected that the application of functional genomic tools in combination with modern approaches such as structure-based drug design and combinatorial chemistry will lead to the development of effective new drugs against drug-resistant malaria strains. This review discusses novel molecular targets of the malaria parasite available to the drug discovery scientist.
Jana
Snehasis
S
Metabolism and Pharmacokinetics Division, Ranbaxy Research Laboratories, Plot-18, Sector-20, Udyog Vihar, Industrial Area, Gurgaon, Haryana 122015, India.
Paliwal
Jyoti
J
D000818:Animals; D000962:Antimalarials / Q000494:pharmacology*; D020650:Combinatorial Chemistry Techniques; D015195:Drug Design; D004351:Drug Resistance; D023281:Genomics; D006801:Humans; D008288:Malaria / Q000188:drug therapy; D010961:Plasmodium / Q000187:drug effects* / Q000235:genetics; D010963:Plasmodium falciparum / Q000187:drug effects / Q000235:genetics
D000962:Antimalarials